A new paradigm for predicting risk of Torsades de Pointes during drug development: Commentary on: “Improved prediction of drug‐induced Torsades de Pointes through simulations of dynamics and machine learning algorithms”

Drug‐induced long QT syndrome (diLQTS) is a clinical entity in which administration of a drug produces marked prolongation of the QT interval on the ECG. DiLQTS places a patient at risk of developing Torsades de Pointes (TdP), a malignant polymorphic ventricular tachycardia associated with arrhythmic sudden cardiac death (SCD). In addition to diLQTS, other clinical risk factors for TdP include female gender, bradycardia, electrolyte disturbances, recent conversion to normal (sinus) rhythm, and congenital LQTS.

[1]  D. Roden,et al.  Screening for Acute IKr Block Is Insufficient to Detect Torsades de Pointes Liability: Role of Late Sodium Current , 2014, Circulation.

[2]  Jørgen K. Kanters,et al.  In silico cardiac risk assessment in patients with long QT syndrome: type 1: clinical predictability of cardiac models. , 2012, Journal of the American College of Cardiology.

[3]  D. Darbar,et al.  Proarrhythmic and Torsadogenic Effects of Potassium Channel Blockers in Patients. , 2016, Cardiac electrophysiology clinics.

[4]  Henggui Zhang,et al.  High-throughput screening of drug-binding dynamics to HERG improves early drug safety assessment. , 2013, American journal of physiology. Heart and circulatory physiology.

[5]  Jonathan H Seltzer,et al.  Cardiovascular Safety Outcome Trials: A meeting report from the Cardiac Safety Research Consortium. , 2015, American heart journal.

[6]  David S. Rosenbaum,et al.  Circadian rhythms govern cardiac repolarization and arrhythmogenesis , 2012, Nature.

[7]  D. Bers.  Cardiac excitation–contraction coupling , 2002, Nature.

[8]  I. Cohen,et al.  Suppression of Phosphoinositide 3-Kinase Signaling and Alteration of Multiple Ion Currents in Drug-Induced Long QT Syndrome , 2012, Science Translational Medicine.

[9]  E. Sobie,et al.  Improved Prediction of Drug‐Induced Torsades de Pointes Through Simulations of Dynamics and Machine Learning Algorithms , 2016, Clinical pharmacology and therapeutics.

[10]  D. Roden,et al.  Flecainide prevents catecholaminergic polymorphic ventricular tachycardia in mice and humans , 2009, Nature Medicine.

[11]  Gary Gintant,et al.  Rechanneling the cardiac proarrhythmia safety paradigm: a meeting report from the Cardiac Safety Research Consortium. , 2014, American heart journal.